12:00 AM
 | 
Aug 14, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 8/11 cls
Advancis (AVNC) Pacific Growth Y. Katherine Xu Upgrade Buy (from neutral) 32% $4.50
Xu said positive Phase III data for Amoxicillin Pulsys to treat tonsillitis/pharyngitis due to Group A streptococcal infection validates the company's Pulsys platform (see B10). AVNC plans to submit an NDA in late 2006 or early 2007.
Amylin (AMLN) Lazard Matthew Osborne New Sell -13% $41.23
Osborne set a $32 target. He said a recent survey showed that about two-thirds of primary care physicians and endocrinologists would try...

Read the full 604 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >